Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Doxorubicin + Nerofe |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Doxorubicin | Adriamycin | Adria|ADR|Doxorubicin hydrochloride|Hydroxydaunorubicin | Chemotherapy - Anthracycline 13 TOPO2 inhibitor 5 | Adriamycin (doxorubicin) is an anthracycline chemotherapeutic, in a non-liposomal formulation, which intercalates into DNA and inhibits topoisomerase II (PMID: 24367159). Doxorubicin is FDA approved for multiple cancer types (FDA.gov). |
| Nerofe | Tumor-Cells Apoptosis Factor Hormone-Peptide|dTCApFs | Nerofe is a 14-amino acid hormone peptide derived from tumor-cells apoptosis factor (TCApF), which potentially induces tumor cell apoptosis, decreases tumor angiogenesis, and enhances antitumor immune response (PMID: 29423221, PMID: 29285362). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05661201 | Phase I | Doxorubicin + Nerofe | NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors | Recruiting | USA | 0 |